Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth.
Combination therapy may benefit patients with specific genetic subtype of non-small cell lung cancer
Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists report in the January issue of Cancer Cell. The findings suggest that identifying such patients and treating them with a combination of drugs from the very start of therapy can produce longer remissions.
The study involves NSCLC tumors which are driven by a mutation in the gene EGFR. Such tumors, which account for about 12 percent of all NSCLC cases in the United States, often recede when treated with a tyrosine kinase inhibitor such as Tarceva or Iressa, which targets the faulty EGFR protein.
A few years ago, this same group of investigators showed that NSCLCs being held in check by Tarceva can switch on an alternate growth circuit if they have too many copies of a gene called MET. Such tumors are considered Tarceva- and Iressa-resistant.
In the new paper, investigators led by Pasi Jänne, MD, PhD, of Dana-Faber, and Jeffrey Engelman, MD, PhD, of MGH, found that some patients with EGFR-mutant lung cancers harbor a small number of tumor cells with an overabundance, or "amplification," of MET even before treatment with a tyrosine kinase inhibitor, and that those few cells are enough to spark drug resistance. One of the triggers for resistance, the researchers found, is HGF, a ligand or "hook" that activates the MET protein.
When activated, HGF works through two entirely different channels to produce drug resistance, the authors report. First, it can generate cell-growth signals through a protein called GAB1. Second, it expands the number of MET-amplified cancer cells, ensuring they will become the dominant type in the lung tumors.
"Not only can HGF spur cell growth on its own, it can speed up the process by which MET-amplified cells emerge and take over the composition of the tumor," says Jänne, who was co-senior author of the paper with Engelman. In about 20 percent of NSCLC patients who are resistant to Tarceva the mechanism is amplification of MET, and in another 20 percent it may involve HGF.
The findings suggest that patients whose NSCLC tumors harbor even a few MET-amplified cells prior to treatment would benefit from drugs that specifically target those cells, in combination with a tyrosine kinase inhibitor. Jänne notes that such drugs are already being studied in clinical trials.
"Our findings provide a strong rationale for combination treatment strategies as initial therapies for some patients," Jänne remarks. "This is especially the case in patients with evidence of pre-existing MET amplifications."
Engelman adds, "A thorough analysis of a patient's cancer prior to treatment can establish how it would ultimately develop resistance to therapy, allowing us to tailor treatment with greater precision to prevent resistance. For example, cancers found to harbor a small population of cells with pre-existing MET amplification will likely benefit from adding MET inhibitors to initial treatment. Those without such cells may not benefit, and these patients can avoid the added toxicity of MET inhibitors and instead focus on other strategies to prevent their cancers from becoming resistant." Engelman is an assistant professor of medicine and Jänne an associate professor of medicine at Harvard Medical School.
The study was supported by grants from the National Institutes of Health, American Association for Cancer Research, the V Foundation, American Cancer Society, Hazel and Samuel Bellin Research Fund, and the Ellison Foundation.
The study's co-lead authors were Alexa Turke of MGH, and Kreshnik Zejnullahu, of Dana-Farber. Co-authors include Yi-Long Wu, of Guangdong General Hospital, Guangzhou, China; Youngchul Song, Dora Dias-Santagata, PhD, Eugene Lifshits, Lecia Sequist, MD, MPH, Sara Akhavanfard, MD, Beow Yeap, and A. John Iafrate, MD, PhD, of MGH; Luca Toschi, MD, Andrew Rogers, and Marzia Capelletti of Dana-Farber; Tony Mok, MD, of the Chinese University of Hong Kong; Neal Lindeman, MD, Carly Murphy, Yun Xiao, and Charles Lee, PhD, of Brigham and Women's Hospital; and James Christensen, of Pfizer Global Research and Development, La Jolla, Calif.
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.
Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $600 million and major research centers in AIDS, cardiovascular disease, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transportation biology, and photomedicine.
Media Contacts: Katie Marquedant, firstname.lastname@example.org, 617 726-0337
Bill Schaller, Dana-Farber, 617 632-5357
U.S. News & World Report ranks Mass General #1 in New England and #2 in the nation based on our quality of care, patient safety and reputation in 16 clinical specialties.
Search the archive for previously published news articles, press releases and publications.
Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.